Abstract
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a well-defined entity. Dupilumab was the first authorized drug for effective treatment of CRSwNP. Nevertheless, it may lead to side effects including an increase in the absolute eosinophil count.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
